End-of-day quote
Shanghai S.E.
06:00:00 2024-04-29 pm EDT
|
5-day change
|
1st Jan Change
|
21.77
CNY
|
+2.01%
|
|
+2.69%
|
+17.04%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
13,614
|
12,508
|
13,948
|
18,276
|
18,992
|
22,227
|
-
|
-
|
Enterprise Value (EV)
1 |
11,835
|
10,105
|
13,948
|
18,276
|
18,992
|
22,227
|
22,227
|
22,227
|
P/E ratio
|
12.9
x
|
12.4
x
|
14.9
x
|
15.9
x
|
14.3
x
|
14.9
x
|
13.2
x
|
12.2
x
|
Yield
|
2.33%
|
2.42%
|
-
|
-
|
1.38%
|
1.38%
|
1.56%
|
-
|
Capitalization / Revenue
|
1.45
x
|
1.47
x
|
1.53
x
|
1.93
x
|
1.86
x
|
1.96
x
|
1.76
x
|
1.73
x
|
EV / Revenue
|
1.45
x
|
1.47
x
|
1.53
x
|
1.93
x
|
1.86
x
|
1.96
x
|
1.76
x
|
1.73
x
|
EV / EBITDA
|
8.39
x
|
7.8
x
|
8.8
x
|
9.48
x
|
8.86
x
|
9.58
x
|
8.62
x
|
8.28
x
|
EV / FCF
|
11,339,571
x
|
11,859,366
x
|
-
|
-
|
18,451,781
x
|
-
|
-
|
-
|
FCF Yield
|
0%
|
0%
|
-
|
-
|
0%
|
-
|
-
|
-
|
Price to Book
|
1.58
x
|
1.35
x
|
1.41
x
|
1.86
x
|
1.74
x
|
1.83
x
|
1.64
x
|
1.49
x
|
Nbr of stocks (in thousands)
|
1,043,238
|
1,043,238
|
1,043,238
|
1,021,567
|
1,021,061
|
1,020,978
|
-
|
-
|
Reference price
2 |
13.05
|
11.99
|
13.37
|
17.89
|
18.60
|
21.77
|
21.77
|
21.77
|
Announcement Date
|
3/20/20
|
3/18/21
|
3/24/22
|
3/27/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
9,381
|
8,504
|
9,112
|
9,447
|
10,222
|
11,360
|
12,645
|
12,878
|
EBITDA
1 |
1,623
|
1,605
|
1,585
|
1,928
|
2,142
|
2,320
|
2,579
|
2,684
|
EBIT
1 |
1,262
|
1,229
|
1,137
|
1,406
|
1,515
|
1,780
|
2,007
|
2,178
|
Operating Margin
|
13.46%
|
14.46%
|
12.48%
|
14.88%
|
14.82%
|
15.67%
|
15.87%
|
16.92%
|
Earnings before Tax (EBT)
1 |
1,262
|
1,215
|
1,121
|
1,415
|
1,567
|
1,788
|
2,016
|
2,188
|
Net income
1 |
1,055
|
1,005
|
935.7
|
1,164
|
1,333
|
1,521
|
1,714
|
1,862
|
Net margin
|
11.25%
|
11.82%
|
10.27%
|
12.32%
|
13.04%
|
13.39%
|
13.55%
|
14.45%
|
EPS
2 |
1.011
|
0.9635
|
0.8969
|
1.124
|
1.300
|
1.463
|
1.647
|
1.790
|
Free Cash Flow
|
1,201
|
1,055
|
-
|
-
|
1,029
|
-
|
-
|
-
|
FCF margin
|
12.8%
|
12.4%
|
-
|
-
|
10.07%
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
73.96%
|
65.73%
|
-
|
-
|
48.04%
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
113.79%
|
104.93%
|
-
|
-
|
77.21%
|
-
|
-
|
-
|
Dividend per Share
2 |
0.3040
|
0.2900
|
-
|
-
|
0.2570
|
0.3000
|
0.3400
|
-
|
Announcement Date
|
3/20/20
|
3/18/21
|
3/24/22
|
3/27/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2024 Q1
|
---|
Net sales
1 |
2,835
|
EBITDA
|
-
|
EBIT
|
-
|
Operating Margin
|
-
|
Earnings before Tax (EBT)
|
-
|
Net income
1 |
416.1
|
Net margin
|
14.68%
|
EPS
|
-
|
Dividend per Share
|
-
|
Announcement Date
|
4/25/24
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
1,779
|
2,404
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
1,201
|
1,055
|
-
|
-
|
1,029
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
12.9%
|
11.3%
|
9.78%
|
11.7%
|
12.4%
|
12.3%
|
12.5%
|
11.9%
|
ROA (Net income/ Total Assets)
|
9.78%
|
8.49%
|
-
|
-
|
8.71%
|
9.3%
|
9.55%
|
9.5%
|
Assets
1 |
10,792
|
11,846
|
-
|
-
|
15,298
|
16,351
|
17,944
|
19,595
|
Book Value Per Share
2 |
8.250
|
8.910
|
9.490
|
9.610
|
10.70
|
11.90
|
13.30
|
14.70
|
Cash Flow per Share
2 |
1.380
|
1.300
|
1.290
|
1.290
|
1.570
|
1.870
|
2.140
|
2.340
|
Capex
1 |
239
|
305
|
480
|
522
|
602
|
705
|
797
|
643
|
Capex / Sales
|
2.55%
|
3.59%
|
5.27%
|
5.52%
|
5.88%
|
6.21%
|
6.3%
|
5%
|
Announcement Date
|
3/20/20
|
3/18/21
|
3/24/22
|
3/27/23
|
3/21/24
|
-
|
-
|
-
|
Last Close Price
21.77
CNY Average target price
25.58
CNY Spread / Average Target +17.50% Consensus |
1st Jan change
|
Capi.
|
---|
| +17.04% | 3.07B | | +26.08% | 662B | | +21.85% | 546B | | -4.77% | 359B | | +16.97% | 323B | | +5.69% | 290B | | +13.68% | 234B | | +3.65% | 198B | | -11.12% | 194B | | +8.08% | 167B |
Other Pharmaceuticals
|